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Abstract
Background: Surgical resection is the preferred treatment of potentially curable esophageal
cancer. To improve long term patient outcome, many institutes apply neoadjuvant
chemoradiotherapy. In a large proportion of patients no response to chemoradiotherapy is
achieved. These patients suffer from toxic and ineffective neoadjuvant treatment, while appropriate
surgical therapy is delayed. For this reason a diagnostic test that allows for accurate prediction of
tumor response early during chemoradiotherapy is of crucial importance. CT-scan and endoscopic
ultrasound have limited accuracy in predicting histopathologic tumor response. Data suggest that
metabolic changes in tumor tissue as measured by FDG-PET predict response better. This study
aims to compare FDG-PET and CT-scan for the early prediction of non-response to preoperative
chemoradiotherapy in patients with potentially curable esophageal cancer.
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BMC Medical Physics 2008, 8:3 http://www.biomedcentral.com/1756-6649/8/3Methods/design: Prognostic accuracy study, embedded in a randomized multicenter Dutch trial
comparing neoadjuvant chemoradiotherapy for 5 weeks followed by surgery versus surgery alone
for esophageal cancer. This prognostic accuracy study is performed only in the neoadjuvant arm of
the randomized trial. In 6 centers, 150 consecutive patients will be included over a 3 year period.
FDG-PET and CT-scan will be performed before and 2 weeks after the start of the
chemoradiotherapy. All patients complete the 5 weeks regimen of neoadjuvant
chemoradiotherapy, regardless the test results. Pathological examination of the surgical resection
specimen will be used as reference standard. Responders are defined as patients with < 10% viable
residual tumor cells (Mandard-score).
Difference in accuracy (area under ROC curve) and negative predictive value between FDG-PET
and CT-scan are primary endpoints. Furthermore, an economic evaluation will be performed,
comparing survival and costs associated with the use of FDG-PET (or CT-scan) to predict tumor
response with survival and costs of neoadjuvant chemoradiotherapy without prediction of
response (reference strategy).
Discussion: The NEOPEC-trial could be the first sufficiently powered study that helps justify
implementation of FDG-PET for response-monitoring in patients with esophageal cancer in clinical
practice.
Trial registration: ISRCTN45750457
Background
Worldwide, esophageal cancer is sixth on the list of cancer
related mortality causes. In the Western world the total
incidence of esophageal cancer is rising, mainly as the
result of a six fold increase in the incidence of adenocarci-
noma over the last decades. [1] In the Netherlands
approximately 1,500 new patients are annually diagnosed
with esophageal cancer.
Surgical resection is currently the preferred curative treat-
ment for esophageal cancer. In the Netherlands 300 – 400
patients per year are candidates for surgery with curative
intent. [2] Even if esophageal cancer resection is only per-
formed with curative intent, in approximately 30% of
these patients the resection is microscopically irradical
and 5-year survival rate among all operated patients is
only 30–40%.[3,4]In order to enhance both locoregional
and systemic tumor control, neoadjuvant treatment has
been introduced. Internationally, many institutes apply
neoadjuvant chemoradiotherapy to improve long term
outcome, especially after the publication of a meta-analy-
sis with favorable results comparing neoadjuvant chemo-
radiotherapy followed by surgery versus surgery alone. [5]
However, in a proportion of patients insufficient objective
response is achieved. These non-responding patients do
not benefit from neoadjuvant therapy, but do suffer from
toxic side effects like hair loss, nausea/vomiting, bone
marrow depression (with risk of septic complications)
and radiation-induced esophagitis (with further weight
loss). This negative impact on the general condition of the
patient probably leads to an increased perioperative mor-
bidity and protracted postoperative recovery. Moreover,
prolonged but ineffective preoperative treatment will
inevitably delay appropriate surgical therapy. This down-
side of neoadjuvant chemoradiotherapy in non-respond-
ers limits its general application in current esophageal
cancer treatment. It underlines the need for early identifi-
cation of non-responders.
Recently, the favorable effect of neoadjuvant chemoradio-
therapy was confirmed in a Dutch phase-II trial, which
tested a regimen of five weekly cycles of chemotherapy
(paclitaxel and carboplatin) and 23 sessions of radiother-
apy (daily dose of 1.8 Gy to a total dose of 41.4 Gy) in a
group of 54 patients. The pathological complete response
rate was 25%, and an additional 36.5% had less than 10%
vital residual tumour cells. The remaining patients
showed no response.[6] Because of these promising
results, this same regimen will now be tested in a rand-
omized, multicenter, Dutch phase-III trial, which offers an
ideal opportunity to assess the accuracy of 18F-fluoro-
deoxyglucose (FDG) positron emission tomography
(PET) and spiral computed tomography-scan(CT) for the
early prediction of non-response in the multimodality
treatment arm.
At present, there are no clinical pretreatment characteris-
tics (e.g. dysphagia), nor any biochemical or pathological
markers that predict the response of an individual tumor
to neoadjuvant chemoradiotherapy. Conventional imag-
ing techniques for monitoring non-surgical therapy, such
as CT and endoscopic ultrasound (EUS), are based on
morphologic imaging. General restrictions of these meth-
ods include difficulty in distinguishing viable tumor from
necrotic or fibrotic tissue and delay between cell kill and
tumor shrinkage. [7] Nevertheless, CT-scanning is stillPage 2 of 7
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availability. EUS is hardly used for response assessment
because of its limited accuracy and poor reproducibility.
Moreover, EUS is discomfortable and not always feasible,
especially in case of postradiation esophagitis or severe
stricturing. [8]
A more accurate diagnostic modality that would be able to
predict tumor response early in the course of neoadjuvant
treatment is considered of crucial importance. FDG-PET
has been shown sensitive in malignant lymphoma and
non-small cell lung cancer for early assessment of tumor
response to therapy and it has achieved promising results
in several other malignancies (e.g. breast cancer, head and
neck cancer). [9-12] In esophageal cancer the evaluation
of FDG-PET for early monitoring of non-surgical therapy
response is described in several small studies and in one
large phase II trial, with promising results. [13-18] In this
last trial non-responders discontinued chemotherapy
after two weeks while responders underwent a total of 14
weeks of chemotherapy. Results show that PET is able to
identify all patients who appear to be histopathological
responders after resection. A large study investigating the
ability of FDG-PET to identify responders to chemoradia-
tion therapy has not yet been performed. Therefore, a
large study with sufficient power to determine whether
PET-scan may improve differentiation between respond-
ing and non-responding esophageal tumors early in the
course of chemoradiation therapy is needed.
Methods/design
Study objectives
The objective of the NEOPEC-trial is to assess the accuracy
and negative predictive value of FDG-PET and CT-scan for
the early prediction of non-response to preoperative
chemoradiotherapy in patients with potentially curable
esophageal cancer. These parameters are defined as pri-
mary endpoints.
Secondly, the correlation between tumor response as pre-
dicted by FDG-PET and CT-scan or as measured by his-
topathologic assessment in the resection specimen and
long term survival will be determined. This correlation
will be used as a secondary endpoint.
Study design
In September 2004 a multicenter randomized phase-III
trial (175 patients in each arm) was initiated (CROSS
trial) in the Netherlands, comparing neoadjuvant chemo-
radiotherapy followed by surgery with surgery alone in
patients with potentially curable esophageal cancer. Long
term survival and quality of life are the primary endpoints
in this therapy-related trial. (ISRCTN80832026)
The present research proposal comprises serial FDG-PET
and CT-scan before and during neoadjuvant therapy in
the multimodality treatment arm of the randomized trial.
Finally, resection specimens will be assessed for tumor
response. Figure 1 describes the logistic integration of the
NEOPEC-trial within the CROSS-trial.
Patient selection
Patients with histologically proven squamous cell carci-
noma or adenocarcinoma of the esophagus or gastro-
esophageal junction will undergo extensive preoperative
staging, including spiral CT-scan of the chest and abdo-
men. The tumor must not extend more than 2 cm into the
gastric cardia. Longitudinal tumor length must not exceed
8 cm, radial size must not exceed 5 cm. cT1N0 tumors are
not eligible. In the absence of local irresectability and/or
distant dissemination patients with an acceptable general
condition (ECOG performance status 0, 1, 2; weight loss
< 10%) will be invited to participate in the randomized
trial. After written, voluntary, informed consent and strat-
ification for tumor type, treatment center, clinical lymph
node status, and WHO performance the patients will be
randomized between the two treatment-arms (neoadju-
vant chemoradiation followed by surgery versus surgery
alone). Patients who are randomized for the neoadjuvant
arm will consequently be asked to participate in the NEO-
PEC-trial.
Concurrent chemoradiotherapy CROSS-trial
Over a 5 week period concurrent chemoradiotherapy is
applied on an outpatient basis.
Paclitaxel (50 mg/m2) and carboplatin (area-under-curve
= 2) are administered by i.v. infusion on days 1, 8, 15, 22,
and 29. Additional medication consists of dexamethason,
clemastine, ranitidine, and ondansetron. Vital signs are
monitored every fifteen minutes during paclitaxel admin-
istration.
External beam radiation with a total dose of 41.4 Gy is
given in 23 fractions of 1.8 Gy, 5 fractions a week, starting
the first day of the first cycle of chemotherapy. Radiation
therapy will be delivered using a multiple field technique.
All patients will undergo 3-D planning using a 3-D con-
formal technique.
Surgery
Surgery, i.e. either transhiatal (1 field lymphadenectomy)
or transthoracic (2 field lymphadenectomy) esophagec-
tomy including lymph node dissection around the celiac
axis, will be performed within 6 weeks of randomization
(surgery alone arm) or within 6 weeks after completion of
the chemoradiation (multimodality treatment arm). For
esophageal surgery a clear correlation has been shown
between hospital volume and quality of care. Therefore,Page 3 of 7
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per year participate in this trial.
Evaluation of tumor response by FDG-PET and spiral CT
PET-scan and CT scan will be performed at baseline and at
day 15. FDG uptake in the tumor will be assessed semi
quantitatively. PET-scans will be performed in several PET
centers, using standardized acquisition and image recon-
struction, with centralized data-analysis (VUMC PET data-
analysis center) and after inter institute calibration of
scanners. [19,20]
For quantitative analysis of FDG uptake the standardized
uptake value (SUV) and the simplified kinetic method
will be assessed using previously validated methodology.
[9,10,12,20-22] Serum glucose levels will be measured
using the standard hexokinase method. Fractional
changes of FDG-uptake between baseline and early during
treatment will be correlated with tumor response in the
resection specimen. Further ROC analysis will be per-
formed in order to obtain an optimal cut-off value of
decrease in FDG uptake for the prediction of non-
responders.
A target CT will be performed using a multi-slice CT scan-
ner (minimal four-slice CT-scanner) after administration
of 100 ml low osmolar intra venous contrast medium.
After a 25 second delay a spiral scan CT is performed tar-
geted at the esophagus and esophagogastric junction
including the maximal extension of the tumor (maximum
slice thickness 3 mm, maximum pitch ≤ 1.5, 150 mAs)
with inferior-superior scanning. Scan settings concerning
spatial resolution and contrast timing will be identical for
pre- and post-treatment CT-scans. The tumor area will be
calculated quantitatively by 3D volume measurement and
multiplication of the greatest tumor diameter and the
greatest perpendicular distance in the axial plane, as this
is the clinically accepted method. [23,24] A decrease in
tumor area or tumor volume of at least 50% is defined as
tumor response. However, as for the FDG-PET data, ROC
analysis will be performed to assess the optimal cut-off
value for tumor response.
Evaluation of tumor response in the resection specimen: 
reference standard
The 'reference standard' of the post-chemoradiation dis-
ease stage will be based on the histology in the surgical
integration NEOPEC-trial within CROSS-trialFigu e 1
integration NEOPEC-trial within CROSS-trial. CRT chemoradiotherapy, PET positron emission tomography, CT com-
puted tomography.Page 4 of 7
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according to the Mandard-score which is based on the per-
centage of viable residual tumor cells in relation to fibro-
sis/necrosis. [25] Responders are defined as patients with
< 10% viable residual tumor cells; non-responders are
defined as patients with > 10% viable residual tumor cells.
Analysis
The accuracy of early FDG-PET and CT-scan in distin-
guishing responders from non-responders will be deter-
mined by using ROC-analysis to show the effect of
different thresholds in early response to identify non-
responders. Additional analyses will focus on the best cut-
off points for PET- and CT-measurements to obtain the
most effective approach for costs and quality of care.
Sample size calculation
The sample size calculation is based on two considera-
tions. First, to compare the accuracy between PET and CT
in distinguishing responders from non-responders, the
area under the ROC curve (AUC) will be used. Based on
results of a previously publicized meta-analysis, the
expected difference in AUC between PET and CT is 0.87
vs. 0.54. [7] To detect such a difference in an unpaired
design, approximately 80 patients are required (with a
power of 80% and a significance level of 5%), assuming
that the proportion of responding patients is 50% (i.e. 40
responders in a group of 80 patients). [6,26]
Second, to be useful in clinical practice the best strategy to
measure early treatment response (supposedly PET)
should have a sufficiently high negative predictive value.
At this moment, it is anticipated that the negative predic-
tive value should be at least 0.80. Based on an expected
sensitivity (true responders correctly identified by PET) of
95% and specificity (true non-responders correctly identi-
fied by PET) of 70%, 130 patients are needed to ensure
that the lower limit of the exact 95% confidence interval
around the negative predictive value will not reach below
0.80 (expected value of negative predictive value is then
0.93; 95% CI 0.83 to 0.99). The total number of 130
patients is based on the assumption that the proportion of
responders will be 50%.
Therefore, a sample size of 130 evaluable patients is
needed to answer both primary research questions. Antic-
ipating a drop-out of 20 patients for various reasons after
initial inclusion, we plan to include a total number of 150
patients in 3 years.
Economic evaluation
The use of FDG-PET and CT-scan in all patients will
increase costs however early discontinuation will reduce
the costs of neoadjuvant treatment in those timely
detected as non-responders. Therefore, the economic eval-
uation will be designed as a cost-effectiveness study.
The reference strategy is neoadjuvant treatment in all
patients, without imaging to predict early response. The
alternative strategies are FDG-PET or CT-scan in all
patients and early discontinuation of neoadjuvant treat-
ment in patients who test as negative (non-response). We
will compare the incremental costs of these alternative
strategies and the associated changes in survival and qual-
ity of life, relative to the reference strategy.
Cost analysis
We will estimate the direct medical costs and indirect
(time) costs for all strategies by documenting resource uti-
lization by counting volumes and using unit prices. The
relevant cost items include: FDG-PET, CT-scan, neoadju-
vant chemoradiotherapy (including the management of
associated morbidity), surgery (distinguishing between
patients with and without neoadjuvant treatment), and
after hospital discharge: out-patient consultations, out-of-
hospital consultations and hospital re-admissions.
Volume data will be collected through patient-specific
case record forms and data retrieval from hospital infor-
mation systems. Standard unit prices will be derived from
the Dutch guideline on unit costing for economic evalua-
tions in health care, from actual unit costing in the partic-
ipating hospitals related to Dutch Diagnosis Related
Groups (DBC) billing system, from previous research, and
from charges in case of volume data of lesser signifi-
cance.[27] The unit costs derived from multiple centers
will be averaged.
Data-analysis
A decision analytic approach will be used to compare the
overall survival, quality of life and costs of the three strat-
egies: neoadjuvant chemoradiotherapy in all patients,
without prediction of treatment response, FDG-PET to
predict tumor response, with early discontinuation of
chemoradiotherapy in patients with non-response and
CT-scan to predict tumor response, with early discontinu-
ation in patients with non-response.
Ethical approval
The present study was approved by the Medical Ethics
Committee of the Academic Medical Center in Amster-
dam, the Netherlands, with reference number MEC 04/
210.
Discussion
Nearly half of the patients receiving neoadjuvant therapy
for esophageal cancer show no or little tumor-response.
They suffer from toxic side-effects of chemotherapy and
radiation-induced esophagitis, while appropriate surgicalPage 5 of 7
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benefit greatly from a test able to distinguish responders
from non-responders, early in the course of neoadjuvant
therapy.
Conventional staging modalities (CT and EUS) appear
not able to monitor early response sufficiently, probably
due to difficulty in distinguishing viable tumor from
necrotic or fibrotic tissue and delay between cell kill and
tumor shrinkage.[7,8] It seems that another test is needed
for this purpose.
When FDG-PET would be implemented for response
monitoring in future clinical practice, a negative test (i.e.
no response on PET) implies that chemoradiotherapy will
be discontinued. If the negative predictive value of PET is
not sufficiently high, this would too often lead to errone-
ous discontinuation of chemoradiotherapy in responders,
incorrectly classified by PET as being non-responders. The
balance in positive and negative consequences associated
with false-negative and false-positive test results will even-
tually determine which negative predictive value is suffi-
ciently high. Ultimately, the results of the randomized
therapeutic trial, especially the additional therapeutic
effectiveness and side-effects of chemoradiotherapy, will
be used to find the optimal balance.
Until now, early response monitoring in patients with
esophageal cancer with FDG-PET has been studied only in
relatively small trials and one larger trail in which patients
discontinued chemotherapy when identified as non-
responder. [13-18] Results of a sufficiently powered study
with fully standardized PET-procedures may help to jus-
tify implementation of FDG-PET for response-monitoring
of chemoradiation therapy in clinical practice.
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